Last reviewed · How we verify
MCI-186 in open label phase
MCI-186 is a free radical scavenger.
MCI-186 is a free radical scavenger. Used for Ischemic stroke.
At a glance
| Generic name | MCI-186 in open label phase |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Free radical scavenger |
| Modality | Small molecule |
| Therapeutic area | Neuroprotection |
| Phase | Phase 3 |
Mechanism of action
MCI-186 works by neutralizing free radicals, which are unstable molecules that can cause oxidative stress and damage to cells. This can help to reduce inflammation and protect against cell death.
Approved indications
- Ischemic stroke
Common side effects
- Headache
Key clinical trials
- Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube (PHASE1)
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (PHASE3)
- Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) (PHASE3)
- A Study of TTYP01 in Healthy Adult Subjects (PHASE1)
- Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCI-186 in open label phase CI brief — competitive landscape report
- MCI-186 in open label phase updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI